Development, equivalence study, and normative data of version B of the Spanish-language Free and Cued Selective Reminding Test

Grau-Guinea, L.; Enríquez, Carmen Pérez; García-Escobar, G.; Elizarán, C. Arrondo; Cutiño, B. Pereira; Santiago, Marie F; Candini, J. Piqué; Planas, Anna Maria Fernàndez; Paez, M.; Casanova, Jordi Peña; Sánchez‐Benavides, Gonzalo

doi:10.1016/j.nrleng.2018.02.001

Cited by 4 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Four outcomes were recorded: total free recall (TFR; sum of free recall), total recall (TR; sum of free recall + cued recall), delayed free recall (DFR; sum of delayed free recall), and delayed total recall (DTR; free delayed recall + cued delayed recall). Parallel tests were conducted to account for learning and repetition effects, as validated previously [ 18 ].…”

Section: Methodsmentioning

confidence: 99%

Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study

Serrano-Castro,

Ramírez-García,

Cabezudo-Garcia

et al. 2024

CNS Drugs

View full text Add to dashboard Cite

Background and Objective Most second and third generation antiseizure medications (ASMs) are associated with cognitive adverse events, which are a major concern for patients. However, the profile of cognitive adverse events differs between ASMs. This study investigated the effects of cenobamate on cognition in patients with drug-resistant epilepsy (DRE) within the Spanish Expanded Access Program (EAP). Methods This was a retrospective, observational study. Inclusion criteria were age ≥ 18 years, DRE with focal seizures, and availability of cognition assessments and EAP authorization. Data were sourced from the clinical records of patients who took part in the Spanish cenobamate EAP. Primary endpoints included cognition (based on 20 neuropsychological outcomes, including verbal and visuospatial episodic memory, verbal fluency, executive function, working memory, attention, and speed of processing), seizure frequency, and concomitant antiseizure medication (ASM) usage at 6 months. Results The study included 20 patients; 10 patients (50%) had daily seizures, 7 (35%) had weekly seizures and 3 (15%) had monthly seizures. The median number of prior antiseizure medications (ASMs) and concomitant ASMs were 10 and 3, respectively. Mean cenobamate doses were 12.5 mg/day at baseline and 191.2 mg/day at 6 months. There was a statistically significant improvement in cognitive scores between baseline and 6 months for two measures of verbal episodic memory ( p = 0.0056 and p = 0.0013) and one measure of visuospatial episodic memory ( p = 0.011), and a significant worsening in cognitive score for attention ( p = 0.030). At 6 months, 14 patients (70%) had a ≥ 50% reduction in seizure frequency, 3 patients (15%) had a ≥ 90% reduction, and 1 patient (5%) was seizure free. There were significant decreases in the mean number of concomitant ASMs ( p = 0.0009), the sum of the ratios of prescribing daily dose/daily defined dose (total ratio of DDD) for concomitant ASMs ( p < 0.0001), and concomitant ASM drug load ( p = 0.038) between baseline and 6 months. Total ratio of DDD was significantly lower at 6 months for perampanel ( p = 0.0016), benzodiazepines ( p = 0.035), and sodium channel blockers ( p = 0.0005) compared with baseline. Based on analysis of covariance, cognitive tests related to verbal or visuospatial episodic memory (e.g., RT of FCSRT, or ROCFT), executive functions (e.g., TMT-B), and processing speed (some 5-Digit Test subtests) appeared to be closely related to the reduction in pharmacological burden rather than the improvement in seizure control. Conclusions Significant improvements in cognition, seizure frequency, and concomitant ASM usage were obser...

show abstract

Section: Methodsmentioning

confidence: 99%

Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study

Serrano-Castro,

Ramírez-García,

Cabezudo-Garcia

et al. 2024

CNS Drugs

View full text Add to dashboard Cite

show abstract

“…Abnormal cognitive performance was defined as having a scalar score lower than seven (< 7) in one or more cognitive subtests. This cutoff score of less than seven (< 7) was selected to be in line with what is considered clinically relevant, that is aligning with accepted practice in the clinical settings 32 , 33 . The participants also completed the Beck Depression Inventory (BDI) 34 , 35 , the Beck Anxiety Inventory (BAI) 36 , the Starkstein Apathy Scale (SAS) 37 , the Subjective Cognitive Decline Questionnaire (SCD-Q) 38 , the Multidimensional Fatigue Inventory (MFI-20) 39 and the 36-Item Short Form Health Survey (SF-36) 40 – 42 .…”

Section: Methodsmentioning

confidence: 99%

Cognitive profile, neuroimaging and fluid biomarkers in post-acute COVID-19 syndrome

Guillén,

Pérez-Millan,

Falgàs

et al. 2024

Sci Rep

View full text Add to dashboard Cite

We aimed to characterize the cognitive profile of post-acute COVID-19 syndrome (PACS) patients with cognitive complaints, exploring the influence of biological and psychological factors. Participants with confirmed SARS-CoV-2 infection and cognitive complaints ≥ 8 weeks post-acute phase were included. A comprehensive neuropsychological battery (NPS) and health questionnaires were administered at inclusion and at 1, 3 and 6 months. Blood samples were collected at each visit, MRI scan at baseline and at 6 months, and, optionally, cerebrospinal fluid. Cognitive features were analyzed in relation to clinical, neuroimaging, and biochemical markers at inclusion and follow-up. Forty-nine participants, with a mean time from symptom onset of 10.4 months, showed attention-executive function (69%) and verbal memory (39%) impairment. Apathy (64%), moderate-severe anxiety (57%), and severe fatigue (35%) were prevalent. Visual memory (8%) correlated with total gray matter (GM) and subcortical GM volume. Neuronal damage and inflammation markers were within normal limits. Over time, cognitive test scores, depression, apathy, anxiety scores, MRI indexes, and fluid biomarkers remained stable, although fewer participants (50% vs. 75.5%; p = 0.012) exhibited abnormal cognitive evaluations at follow-up. Altered attention/executive and verbal memory, common in PACS, persisted in most subjects without association with structural abnormalities, elevated cytokines, or neuronal damage markers.

show abstract

“…This patient was examined as part of an ongoing study evaluating cognitive impairment after COVID-19, which our local Ethics Committee approved, and the patient gave written informed consent. 2021, FCSRT was administered again using a parallel version (Grau-Guinea et al, 2021).…”

Section: Case Descriptionmentioning

confidence: 99%

“…Full cognitive assessment was performed in October 2020. In March 2021, FCSRT was administered again using a parallel version ( Grau-Guinea et al, 2021 ).…”

Section: Diagnostic Assessmentsmentioning

confidence: 99%

“Brain Fog” by COVID-19 or Alzheimer’s Disease? A Case Report

et al. 2021

View full text Add to dashboard Cite

Cognitive symptoms after COVID-19 have been increasingly recognized several months after the acute infection and have been designated as “brain fog.” We report a patient with cognitive symptoms that started immediately after COVID-19, in which cerebrospinal fluid biomarkers were highly suggestive of Alzheimer’s disease. Our case highlights the need to examine patients with cognitive symptoms following COVID-19 comprehensively. A detailed assessment combining clinical, cognitive, and biomarker studies may help disentangle the underlying mechanisms associated with cognitive dysfunction in each case. The investigation of neurodegenerative processes in an early stage, especially in older patients, is probably warranted.

show abstract

Development, equivalence study, and normative data of version B of the Spanish-language Free and Cued Selective Reminding Test

Cited by 4 publications

References 13 publications

Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study

Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study

Cognitive profile, neuroimaging and fluid biomarkers in post-acute COVID-19 syndrome

“Brain Fog” by COVID-19 or Alzheimer’s Disease? A Case Report

Contact Info

Product

Resources

About